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BACKGROUND
The Systolic Blood Pressure Intervention Trial (SPRINT) showed that tar-
geting a systolic blood pressure (SBP) of ≤ 120 mm Hg (intensive treat-
ment) reduced cardiovascular disease (CVD) events compared to SBP of 
≤ 140 mm Hg (standard treatment); however, it is unclear if this effect is 
similar in all racial/ethnic groups.
METHODS
We analyzed SPRINT data within non-Hispanic White (NHW), non-
Hispanic Black (NHB), and Hispanic subgroups to address this ques-
tion. High-risk nondiabetic hypertensive patients (N = 9,361; 30% NHB; 
11% Hispanic) 50 years and older were randomly assigned to intensive 
or standard treatment. Primary outcome was a composite of the first 
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occurrence of a myocardial infarction, acute coronary syndrome, stroke, 
decompensated heart failure, or CVD death.
RESULTS
Average postbaseline SBP was similar among NHW, NHB, and Hispanics 
in both treatment arms. Hazard ratios (HRs) (95% confidence interval) 
(intensive vs. standard treatment groups) for primary outcome were 0.70 
(0.57–0.86), 0.71 (0.51–0.98), 0.62 (0.33–1.15) (interaction P value = 0.85) 
in NHW, NHB, and Hispanics. CVD mortality HRs were 0.49 (0.29–0.81), 
0.77 (0.37–1.57), and 0.17 (0.01–1.08). All-cause mortality HRs were 0.61 
(0.47–0.80), 0.92 (0.63–1.35), and 1.58 (0.73–3.62), respectively. A test for 
differences among racial/ethnic groups in the effect of treatment assign-
ment on all-cause mortality was not significant (Hommel-adjusted P 
value = 0.062) after adjustment for multiple comparisons.
CONCLUSION
Targeting a SBP goal of ≤ 120 mm Hg compared to ≤ 140 mm Hg led 
to similar SBP control and was associated with similar benefits and risks 
among all racial ethnic groups, though NHBs required an average of 
~0.3 more medications.
CLINICAL TRIALS REGISTRATION
Trial Number NCT01206062, ClinicalTrials.gov Identifier at https://clini-
caltrials.gov/ct2/show/NCT01206062.
Keywords: African Americans; blood pressure; clinical outcomes; clinical 
trials; Hispanics; hypertension; race and ethnicity.
doi:10.1093/ajh/hpx138
Racial and ethnic differences in cardiovascular disease 
(CVD) remain a major public health challenge in the United 
States.1–3 Hypertension is one of the most important, modi-
fiable CVD risk factors leading to coronary heart disease, 
stroke, end-stage renal disease, and overall mortality.4–6 
Non-Hispanic Black (NHB) and Hispanic adults (com-
pared to non-Hispanic Whites [NHWs]) have higher rates 
of uncontrolled blood pressure (BP) (50%, 54%, and 46%, 
respectively), and NHBs are at greater risk of hypertension-
related CVD morbidity and mortality.4 CVD age-adjusted 
death rates are 33% higher among NHBs when compared 
to the overall US population.4,5 Hypertension-related age-
adjusted mortality rates of adults aged 25  years and older 
are 127.2 vs. 135.9 per 100,000 populations for Hispanics vs. 
NHWs, respectively, though considerable heterogeneity in 
CVD risk is seen in Hispanics based on country of origin.7,8 
These disparities cost the US health care system an estimated 
$49 billion per year.2,5,9 Therefore, BP control interventions 
to reduce CVD morbidity and mortality in underrepresented 
racial and ethnic groups are important at both the individual 
and population levels.
Over the past 2 decades, studies have demonstrated that 
lowering BP with antihypertensive medications reduces 
the risk of CVD morbidity and mortality, including in 
NHB and Hispanic populations.10–14 Until recently, there 
was insufficient data to determine optimal BP targets for 
the treatment of hypertension in these populations.2,7 
Lowering systolic BP (SBP) with antihypertensive medica-
tions significantly reduced CVD morbidity and mortality in 
the Systolic Hypertension in the Elderly Program (SHEP), 
Systolic Hypertension in Europe (Syst-Eur) Trial, and the 
Hypertension in the Very Elderly Trial (HYVET).15–17 
However, SBP treatment goals in the more intensive treat-
ment arms of these trials were between 150 and 160 mm 
Hg and only SHEP included African American (AA) par-
ticipants (14%).15,17 Two small trials (with limited statisti-
cal power) that compared a SBP target of <140 mm Hg to 
<160 mm Hg found no significant difference in CVD out-
comes.18,19 The Action to Control Cardiovascular Risk in 
Diabetes BP trial (ACCORD), which included a racially 
diverse population (24% NHBs and 7% Hispanics) of 4,733 
high-risk hypertensives with type 2 diabetes mellitus treated 
to a SBP target <120 mm Hg (compared to SBP <140 mm 
Hg), identified no difference in the primary CVD composite 
outcome but a significant reduction in stroke risk in the 
<120 mm Hg group.20
More recently, random assignment to a SBP target 
<120  mm Hg compared to <140  mm Hg among people 
at high CVD risk (without diabetes or history of stroke) 
resulted in a 25% reduction in the primary outcome (a CVD 
composite) and a 27% reduction in all-cause mortality in 
the National Institutes of Health (NIH) sponsored Systolic 
Blood Pressure Intervention Trial (SPRINT).13,21 Of the 
9,361 SPRINT participants, 30% were NHBs and 11% were 
Hispanic.13,22,23 Exploration of the trial results in non-Black 
compared to Black participants was a prespecified ana-
lysis. Thus, SPRINT provides a large database for the study 
of BP treatment targets in these diverse populations.21 This 




Details of the SPRINT study design and rationale have 
been previously reported and more extensive details of the 
study protocol and procedures are publicly available.13,21,24 
All participants gave written informed consent and the trial 
protocol was approved by the institutional review board 
at each participating site. The SPRINT cohort consisted of 
men and women, aged 50 years or older with a SBP between 
130–180  mmHg on 0–4 antihypertensive medications and 
at high CVD risk. High CVD risk was defined by the pres-
ence of one or more of the following at study entry: clin-
ical or subclinical CVD (other than stroke); chronic kidney 
disease (CKD) defined as an estimated glomerular filtration 
rate calculated with the 4-variable Modification of Diet in 
Renal Disease (MDRD) equation of 20–59 ml/min/1.73 m2 
using the most recent serum creatinine drawn within the 
preceding 6 months; a Framingham Risk Score for 10-year 
CVD risk ≥15%; or age ≥75 years. Individuals with history 
of diabetes, stroke, polycystic kidney disease, or heart failure 
were excluded.21
Race was self-reported by participants as Black (or AA), 
White, Native American, Asian, Native Hawaiian or other 
Pacific Islander, and other; and ethnicity was based upon 
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In this report, the 984 participants who self-identified as 
Hispanic were considered part of that group (regardless of 
self-identified race). Non-Hispanic participants who self-
identified as AA alone were grouped as NHB (n  =  2802). 
Non-Hispanic participants who self-identified as White 
alone were grouped as NHW (n = 5399). Participants who 
self-identified as belonging to other race categories, selected 
more than one race category or did not specify a race were 
excluded from this analysis (n = 176).
Intervention
SPRINT participants were randomly assigned to 1 
of 2 SBP targets standard (SBP <140  mm Hg) or inten-
sive (SBP <120  mm Hg) treatment. SPRINT investigators 
initiated and adjusted antihypertensive medications to 
achieve the assigned SBP targets according to the SPRINT 
step-care treatment algorithm using US Food and Drug 
Administration approved antihypertensive drugs provided 
by the study. At each visit, trained clinical staff measured BPs 
with an automated BP device (Omron-HEM-907 XL) using 
standardized procedures.21,24 BP measurement requirements 
included measuring BP early in the visit and not following 
stressful exam components such as blood draws, proper 
positioning of the participant in a chair with back support, 
and proper cuff size determination. The SPRINT Manual of 
Procedures (MOP) stated that participants should be rest-
ing, not completing questionnaires, and not speaking with 
study staff during the 5-minute rest period or while BP 
measurements were being taken. The MOP also stated that 
staff should leave the room during the 5-minute rest period, 
and provided a script that staff could use to explain that they 
would be absent during the 5-minute rest period and would 
then enter the room and obtain the measurements without 
speaking to the participant.24
Study measures and outcomes
At baseline, information on sociodemographics, cardio-
vascular risk factors, concomitant medications, social and 
medical history, anthropometrics, dementia screening, and 
quality of life measurements were collected on all eligible 
patients. Routine follow-up visits were conducted at 1, 2, 
3, and every 3  months thereafter during the trial. Specific 
laboratory data (e.g., serum creatinine, fasting serum 
glucose) were collected at baseline and every 3  months. 
Additional visits were scheduled as needed for management 
of adverse effects or SBP goal attainment.
The primary outcome was a composite of the first occur-
rence of a myocardial infarction, acute coronary syndrome 
not leading to a myocardial infarction, stroke, decompen-
sated heart failure, or cardiovascular death. Major secondary 
outcomes included CVD mortality, all-cause mortality, and a 
composite of total mortality and the primary outcome. Other 
prespecified secondary outcomes analyzed in this report 
included decline in renal function or development of end-
stage renal disease. Definitions of these outcomes were pro-
spectively defined in the SPRINT protocol.24 Self-reported 
study outcomes were ascertained quarterly by clinical site 
staff using structured interviews for both treatment groups. 
Medical records and other corroborating data were col-
lected for each potential outcome; all study outcomes were 
reviewed and adjudicated by the trial’s outcome commit-
tee using a prespecified protocol and blinded to treatment 
assignment.21,24
In contrast to study outcomes, adverse events, including 
serious adverse events (SAEs), could be reported at any visit. 
SAEs were defined as an adverse experience judged by an 
investigator to be life threatening and/or resulting in death, 
permanent disability, or hospitalization or prolongation of 
hospitalization, whether or not the event was thought to 
be related to study intervention. SPRINT considered any 
emergency visit for heart failure, bradycardia, stroke, tran-
sient ischemic attack, or electrolyte abnormalities, and any 
syncope or injurious falls as a reportable SAE. Clinical and 
laboratory variables (serum potassium, creatinine levels, and 
estimated glomerular filtration rate) were also examined as 
potential adverse effects. An independent Data and Safety 
Monitoring Board (DSMB) monitored unblinded study data 
and provided oversight of participant safety.
Statistical analysis
Descriptive statistics (means and SD for continuous vari-
ables; frequencies and percentages for categorical variables) 
of baseline characteristics were computed by race/ethni-
city and by treatment group within each stratum of race/
ethnicity. Pairwise comparisons (i.e., each race/ethnicity 
compared to the other) were made using 1-way analysis of 
variance with pairwise contrasts for continuous variables 
and separate chi-square tests for categorical variables. Mean 
and SE of follow-up SBP was estimated by race/ethnicity and 
treatment group using mixed linear models with unstruc-
tured variance-covariance to control for within-subject 
correlation. Effect of treatment arm assignment on time to 
the first event within race/ethnicity stratum (i.e., CVD out-
comes, mortality, CKD outcomes, and SAEs) was analyzed 
based on the intention-to-treat approach using univariable 
Cox proportional-hazards regression models for treatment 
arm assignment with 2-sided tests at the 5% level of sig-
nificance and stratification by clinical site. Two-way inter-
actions between treatment effect and race/ethnicity group 
were assessed using likelihood-ratio tests and Hommel’s 
technique to adjust for multiple comparisons. Since the sub-
group definitions in this report differ from the prespecified 
race subgroup of Blacks vs. non-Blacks (in the prespecified 
comparison, the Black group included both Hispanic and 
non-Hispanic ethnicities who self-identified as Black while 
the non-Black group included both Hispanics and non-His-
panics who self-identified as White), outcome data for the 
prespecified race subgroups are presented in the Appendix 
(Supplementary Table S2). All analyses were performed 
using SAS version 9.4 software (SAS Institute, Cary, NC).
Following a recommendation by the trial’s independ-
ent DSMB, the SPRINT BP intervention was halted on 20 
August 2015 by the National Heart, Lung, and Blood Institute 
(NHLBI) Director after a mean follow-up of 3.26  years. 
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a study event in each participant prior to 21 August 2015. 
This publication is based on a database that was frozen on 16 
September 2016 and includes outcome events from baseline 




Figure 1 displays the CONSORT diagram for SPRINT by 
race/ethnicity group. Baseline characteristics by race/ethni-
city and treatment assignment are provided in Table 1 and 
by race/ethnicity, pooled across treatment (Supplementary 
Table S1). After stratifying by race/Hispanic ethnicity, few 
significant differences in baseline characteristics and risk 
profile were noted between treatment groups. Significant 
differences in weight between randomized treatment groups 
were seen in the Hispanic subgroup, statin use in NHBs, and 
aspirin use in NHWs (Table 1).
Blood pressure
SBP levels were similar by race/ethnicity stratum and 
between treatment groups at baseline (Table  1). SBP over 
time is shown in Figure 2. Overall, SBP decreased substan-
tially during the first year of the study in all race/ethnicity 
groups and showed only modest differences between racial/
ethnic groups for both SBP. Average postbaseline mean ± SE 
follow-up SBP in the standard arm was 134.7 ± 0.1 mm Hg 
in NHW, 135.5 ± 0.2 mm Hg in NHB, and 134.8 ± 0.3 mm 
Hg in Hispanic participants; compared to intensive arm val-
ues of 121.8  ±  0.2, 122.6  ±  0.2, and 119.9  ±  0.4 in NHW, 
NHB, and Hispanic participants, respectively. The mean 
number of antihypertensive medications prescribed were 
significantly higher in NHB (mean  ±  SE intensive arm 
3.01 ± 0.03, standard arm 1.99 ± 0.03) compared to in NHW 
(intensive arm 2.74 ± 0.02, standard arm 1.75 ± 0.02; P value 
<0.0001 vs. NHB, both arms), and in Hispanics (intensive 
arm 2.70 ± 0.05, standard arm 1.77 ± 0.05; P value <0.0001 
vs. NHB, both arms) (Figure 2).
Figure 1. Consort diagram. Race/ethnicity was self-reported and participants were classified as: Hispanic regardless of self-identified race; non-His-
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Table 1. Baseline clinical characteristics of SPRINT participants stratified by race/ethnicity and randomized group
Non-Hispanic White (n = 5,399)a Non-Hispanic Black (n = 2,802)a Hispanic (n = 984)a
Characteristics Intensive Standard Intensive Standard Intensive Standard
No. randomized 2,698 2,701 1,379 1,423 503 481
Age
 50–64 782 (29.0) 813 (30.1) 824 (59.8) 831 (58.4) 267 (53.1) 247 (51.4)
 65–74 939 (34.8) 901 (33.4) 329 (23.9) 366 (25.7) 147 (29.2) 149 (31.0)
 ≥75 977 (36.2) 987 (36.5) 225 (16.3) 226 (15.9) 89 (17.7) 85 (17.7)
Female gender 795 (29.5) 757 (28.0) 630 (45.7) 641 (45.1) 225 (44.7) 229 (47.6)
Chronic kidney diseaseb 885 (32.8) 893 (33.1) 325 (23.6) 312 (21.9) 94 (18.7) 96 (20.0)
Cardiovascular disease
 Clinical 526 (19.5) 507 (18.8) 135 (9.8) 144 (10.1) 65 (12.9) 63 (13.1)
 Subclinical 207 (7.7) 222 (8.2) 121 (8.8) 120 (8.4) 47 (9.3) 48 (10.0)
Framingham 10-year CVD risk 
score (%)
26.8 ± 12.8 26.8 ± 12.6 21.7 ± 11.7 21.9 ± 11.8 23.0 ± 12.3 22.4 ± 11.8
Baseline blood pressure
 SBP, mm Hg 139.6 ± 15.5 139.2 ± 15.2 139.5 ± 16.7 140.0 ± 15.8 140.2 ± 14.5 141.2 ± 15.1
 DBP, mm Hg 76.8 ± 11.4 76.5 ± 11.6 81.2 ± 12.5 81.3 ± 12.3 77.6 ± 11.2 77.3 ± 11.2
Pulse, bpm 65.2 ± 11.3 65.2 ± 11.5 68.7 ± 11.9 68.4 ± 11.9 65.4 ± 10.3 66.1 ± 10.7
# of BP Medications 1.78 ± 1.03 1.78 ± 1.05 1.99 ± 1.06 1.96 ± 1.05 1.79 ± 0.97 1.71 ± 0.93
Weight, lbs. 190.0 ± 40.9 191.2 ± 41.4 196.7 ± 42.7 195.7 ± 42.5 180.1 ± 36.3* 175.6 ± 35.3*
BMI, kg/m2 29.4 ± 5.5 29.4 ± 5.4 31.0 ± 6.4 30.8 ± 6.3 29.8 ± 5.3 29.3 ± 5.0
# of chronic diseases 3.02 ± 1.70 3.02 ± 1.74 2.18 ± 1.56 2.20 ± 1.53 2.24 ± 1.64 2.16 ± 1.47
Smoking status
 Current 238 (8.8) 230 (8.5) 324 (23.6) 315 (22.2) 68 (13.6) 45 (9.4)
 Past 1,340 (49.8) 1,340 (50.0) 453 (33.0) 484 (34.2) 157 (31.3) 146 (30.5)
Statin use 1,311 (48.9) 1,338 (50.0) 430 (31.4)† 513 (36.3)† 193 (38.6) 198 (41.3)
Aspirin use 906 (33.8)† 805 (30.1)† 365 (26.7) 364 (25.8) 120 (24.0) 117 (24.4)
Baseline laboratory values
 Fasting glucose (mg/dl) 99.3 ± 13.2 99.5 ± 11.9 98.0 ± 15.3 97.6 ± 16.1 98.3 ± 11.6 98.5 ± 12.2
 Cholesterol, total (mg/dl) 186.4 ± 40.9 186.3 ± 41.1 196.6 ± 42.2 195.2 ± 39.7 192.8 ± 40.3 194.9 ± 40.3
 Cholesterol, LDL (mg/dl) 108.8 ± 34.5 108.2 ± 34.4 119.7 ± 36.4 118.5 ± 34.3 114.1 ± 35.2 115.0 ± 34.2
 Cholesterol, HDL (mg/dl) 52.3 ± 14.1 41.9 ± 14.3 54.9 ± 15.2 55.3 ± 14.9 50.7 ± 12.3 50.6 ± 14.1
 Triglycerides (mg/dl) 127.7 ± 79.3 131.7 ± 83.1 113.1 ± 102.1 110.0 ± 110.3 140.6 ± 68.6 149.8 ± 97.9
 Potassium (mmol/l) 4.28 ± 0.43 4.27 ± 0.42 4.07 ± 0.41 4.08 ± 0.49 4.19 ± 0.43 4.21 ± 0.40
 Sodium (mmol/l) 139.9 ± 2.6 140.0 ± 2.5 140.5 ± 2.3 140.4 ± 2.2 140.3 ± 2.2 140.2 ± 2.3
 eGFR (ml/min/1.73 m2) 68.3 ± 18.1 68.0 ± 18.3 76.3 ± 23.4 76.7 ± 22.3 78.0 ± 22.3 77.2 ± 22.3
 Creatinine (mg/dl) 1.06 ± 0.31 1.07 ± 0.31 1.14 ± 0.40 1.13 ± 0.38 0.96 ± 0.33 0.96 ± 0.34
Plus–minus values are means ± SD: *P < 0.05, †P < 0.01 Standard vs. intensive arms. SI conversion factors: to convert the values for cre-
atinine to micromoles per liter, multiply by 88.4. To convert the values for cholesterol to millimoles per liter, multiply by 0.0259. To convert the 
values for triglycerides to millimoles per liter, multiply by 0.0113. To convert the values for glucose to millimoles per liter, multiply by 0.0555. 
Abbreviations: BMI, Body Mass Index; BP, blood pressure; CVD, cardiovascular disease primary outcome; DBP, diastolic blood pressure; 
eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; SPRINT, 
Systolic Blood Pressure Intervention Trial.
aRace/ethnicity was self-reported and participants were classified as: Hispanic regardless of self-identified race; non-Hispanic Black if self-
identified as African American alone; and non-Hispanic White if self-identified as white alone.
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CVD outcomes
The HRs (95% confidence interval) (intensive vs. stand-
ard treatment groups) for the primary composite outcome 
were 0.70 (0.57–0.86), 0.71 (0.51–0.98), 0.62 (0.33–1.15) in 
NHWs, NHBs, and Hispanics, respectively (Table 2). For CV 
mortality, HRs were 0.49 (0.29–0.81) in NHW, 0.77 (0.37–
1.57) in NHB, and 0.17 (0.01–1.08) in Hispanics, though 
for all-cause mortality they were 0.61 (0.47–0.80) in NHW, 
0.92 (0.63–1.35) in NHB, 1.58 (0.73–3.62) in Hispanics. The 
effect of treatment arm assignment was homogenous with all 
interaction P values >0.05 across racial/ethnic groups for the 
primary CVD outcome, as well as the secondary outcomes 
of myocardial infarction, acute coronary syndrome, stroke, 
heart failure, CVD death, and primary outcome.
There appeared to be heterogeneity of effect for all-
cause mortality and for non-CVD death (interaction P 
value = 0.008 and 0.006, respectively) (Table 2). However, 
after adjusting for multiple comparisons, the treatment by 
race/ethnicity interaction approached significance only for 
all-cause death (Hommel-adjusted P value = 0.062). CVD 
mortality was similarly reduced in all race/ethnic groups 
(treatment by race/ethnic interaction P value  =  0.098), 
including in treatment comparisons by Blacks vs. non-
Blacks (Supplementary Tables S2 and S3), or whether 
Hispanics resided in Puerto Rico (n  =  437) or the US 
mainland (n  =  550) (data not shown). Treatment by resi-
dence interaction P values were 0.40, 0.68, and 0.43 for 
primary outcome, CVD mortality, and all-cause mortality, 
respectively.
CKD outcomes
The effect of treatment arm assignment on CKD out-
comes (stratified by baseline CKD vs. non-CKD subgroup) 
by race/ethnicity is shown in Table  3 and Supplementary 
Table S2. The numbers of events in the CKD subgroup were 
small, particularly for the primary composite renal outcome 
of ≥50% reduction in estimated glomerular filtration rate or 
end-stage renal disease; treatment effects were similar across 
race/ethnicity groups for all 4 outcomes.
Serious adverse events
Results for SAEs are displayed in Table  4. Between the 
2 treatment groups, no heterogeneity of effect was noted 
between the 3 racial ethnic groups in terms of overall SAEs or 
the 6 select SAEs: hypotension, syncope, bradycardia, elec-
trolyte abnormality, injurious falls, or acute kidney injury.
DISCUSSION
We found that targeting a SBP <120  mm Hg compared 
to the currently recommended <140  mm Hg led to simi-
lar reductions in the relative risk for the primary outcome 
across major racial/ethnic groups—NHB (29%), NHW 
(30%), and Hispanics (38%). We also found that although 
NHBs required slightly more antihypertensive therapy to 
achieve this lower target, there was no difference in achieved 
SBP by race in the intensive arm.
Moreover, while statistically significant differences in 
baseline characteristics including cardiovascular risk profile 
(e.g., age, gender, cigarette smoking, prevalent CKD/CVD) 
were seen between the race/ethnic subgroups (Tables 1 and 
Supplementary Table S1), these differences were small. This 
suggests the benefit was unaffected by these population dif-
ferences (though we had limited statistical power to detect 
such an effect). The population impact of implementing 
SPRINT may be even greater among NHBs given the higher 
prevalence of hypertension in this population and the fact 
that hypertension accounts for a greater proportion of CVD 
events among NHB and Hispanics.9
These findings are consistent with those in previ-
ous SPRINT publications13,25 and extends the findings 
of previous studies.26,27 In the Hypertension Detection 
Follow-up trial (HDFP) trial, Blacks (Hispanic ethnicity 
Figure 2. Follow-up SBP and mean number of antihypertensive meds by treatment arm and race/ethnicity. The SBP separation between treatment 
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Table 2. Primary and secondary outcomes stratified by treatment group and race/ethnicity
Outcome Race/ethnicity
Intensive arm Standard arm












Primary outcomea (Non-Hispanic) 
White
2,698 167 1.9 2,701 229 2.7 0.70 0.57 0.86 0.85
(Non-Hispanic) 
Black
1,379 64 1.5 1,423 93 2.1 0.71 0.51 0.98





2,698 69 0.8 2,701 88 1.0 0.77 0.56 1.05 0.63
(Non-Hispanic) 
Black
1,379 22 0.5 1,423 35 0.8 0.64 0.36 1.09





2,698 30 0.3 2,701 26 0.3 1.15 0.68 1.95 0.35
(Non-Hispanic) 
Black
1,379 7 0.2 1,423 9 0.2 0.86 0.30 2.33
Hispanic 503 3 0.2 481 5 0.3 0.57 0.11 2.34
Stroke (Non-Hispanic) 
White
2,698 44 0.5 2,701 49 0.6 0.87 0.58 1.32 0.38
(Non-Hispanic) 
Black
1,379 14 0.3 1,423 22 0.5 0.66 0.33 1.28
Hispanic 503 6 0.4 481 5 0.3 1.05 0.31 3.69
Heart failure (Non-Hispanic) 
White
2,698 40 0.5 2,701 70 0.8 0.55 0.37 0.81 0.27
(Non-Hispanic) 
Black
1,379 22 0.5 1,423 29 0.6 0.80 0.45 1.40





2,698 23 0.3 2,701 45 0.5 0.49 0.29 0.81 0.098
(Non-Hispanic) 
Black
1,379 13 0.3 1,423 18 0.4 0.77 0.37 1.57
Hispanic 503 1 0.1 481 6 0.4 0.17 0.01 1.08
Non-CVD death (Non-Hispanic) 
White
2,698 57 0.6 2,701 82 0.9 0.69 0.49 0.97 0.006
(Non-Hispanic) 
Black
1,379 30 0.7 1,423 26 0.6 1.16 0.68 1.98
Hispanic 503 12 0.7 481 4 0.3 3.28 0.98 14.77
All-cause mortality (Non-Hispanic) 
White
2,698 89 1.0 2,701 144 1.6 0.61 0.47 0.80 0.008
(Non-Hispanic) 
Black
1,379 51 1.2 1,423 56 1.2 0.92 0.63 1.35
Hispanic 503 19 1.1 481 12 0.8 1.58 0.73 3.62




2,698 222 2.6 2,701 310 3.6 0.70 0.59 0.83 0.082
(Non-Hispanic) 
Black
1,379 94 2.2 1,423 122 2.7 0.78 0.59 1.030
Hispanic 503 35 2.1 481 31 2.0 1.00 0.60 1.67
Abbreviations: CI, confidence interval, CVD, cardiovascular disease primary outcome; HR, hazard ratio.
aThe primary outcome includes the first occurrence of myocardial infarction, acute coronary syndrome, stroke, heart failure, or death from 
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was not reported), who made up 44% of study participants, 
had a significant reduction in all-cause mortality with 
more intensive “stepped” care compared to less intensive 
“referred” care.28 While the BP target in HDFP was based 
on a DBP goal of <90 mm Hg, SBP decreased from a base-
line of 159 mm Hg to 130 mm Hg by years 4 and 5.29 In the 
ACCORD trial, the mean on-treatment intensive arm SBPs 
were 119.2 ± 0.2, 122.7 ± 0.4, and 121.7 ± 0.7 in the NHW, 
NHB, and Hispanic groups, respectively (written commu-
nication from P Byrington, November 2016). However, no 
benefit on the composite CVD outcome was seen with the 
<120 mm Hg target, either overall or in subgroups defined 
by race.
No racial or ethnic differences by treatment assignment 
were seen in renal outcomes or in SAEs in SPRINT. The 
AASK trial is the only other renal outcome trial with sig-
nificant numbers of AAs and showed no benefit of more 
intensive therapy in this population with hypertensive renal 
disease except in participants with proteinuria (protein-to-
creatinine ratio of more than 0.22).30,31 The small number 
of renal events in SPRINT make it unable to evaluate this 
finding.
Literature assessing incident CVD mortality in 
Hispanics and NHW found a statistically significant asso-
ciation between Hispanic ethnicity and lower CV and 
all-cause mortality despite having a worse CV risk profile 
when compared to NHW.32 This has been referred to as the 
Hispanic paradox.33 However, the risk profile of Hispanics 
in SPRINT was not greater than that seen in the other 
subgroups and did not result in an all-cause and cardio-
vascular-specific mortality advantage among Hispanics in 
SPRINT. Instead, we note a similar effect size on CV pro-
tection across NHWs, NHBs, and Hispanics. Though the 
sample sizes were small, SPRINT outcomes also did not 
Table 3. CKD outcomes in the CKD and non-CKD subgroups, stratified by treatment group and race/ethnicity
Outcome Subgroup
Intensive arm Standard arm


















885 8 0.3 893 7 0.24 1.14 0.38 3.41 0.76
(Non-Hispanic) 
Black
325 9 0.9 312 8 0.79 1.09 0.40 3.14






365 49 4.3 346 60 5.7 0.79 0.53 1.18 0.17
(Non-Hispanic) 
Black
118 11 3.0 106 18 5.7 0.26 0.08 0.69








1,808 88 1.5 1,798 21 0.4 4.38 2.77 7.24 0.22
(Non-Hispanic) 
Black
1,046 42 1.3 1,103 16 0.5 2.61 1.47 4.83







965 81 2.7 955 101 3.4 0.77 0.57 1.03 0.51
(Non-Hispanic) 
Black
576 45 2.5 642 65 3.4 0.73 0.49 1.08
Hispanic 219 15 2.1 213 15 2.2 0.80 0.36 1.75
Abbreviations: CI, confidence interval, CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.
aFor participants with CKD at baseline, composite renal outcome was the first occurrence of a reduction in eGFR by 50% (measure twice at 
least 90 days apart) or long-term dialysis or kidney transplant.
bIncident albuminuria denotes a urinary albumin to creatinine ratio of less than 10 mg/g at baseline and doubled to a creatinine ratio from less 
than 10 mg/g to 10 mg/g or greater (measured twice at least 90 days apart).
cIncludes a 30% reduction in eGFR (measured twice at least 90 days apart) to an eGFR of less than 60 ml/min/1.73 m2, dialysis, or a kidney 
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differ between Hispanics residing on the US mainland vs. 
those in Puerto Rico.
The strengths of SPRINT include its large sample size, a 
diverse patient population, and its success in both imple-
menting the protocol and achieving the SBP targets and 
difference in SBP between the 2 interventional groups 
throughout the trial, including in NHBs and Hispanics. 
While by design SPRINT was not powered to specifically 
examine treatment effects of the lower SBP goal in these 
subgroups, this analysis supports the benefits of intensive 
BP lowering on the primary composite endpoint which 
was similar across these race/ethnicity groups. A somewhat 
surprising limitation was the baseline characteristics and 
CVD risk profile of the NHB and Hispanic populations in 
Table 4. Selected serious adverse events stratified by treatment group and by race/ethnicity
Outcome Race/ethnicity




N Events % per 
Year




Any SAEa (Non-Hispanic) 
White
2,698 430 5.5 2,701 5.9 17.0 0.93 0.82 1.06 0.24
(Non-Hispanic) 
Black
1,379 146 3.6 1,379 147 3.6 1.02 0.81 1.29
Hispanic 503 42 2.7 481 29 1.9 1.40 0.87 2.24
Hypotension (Non-Hispanic) 
White
2,698 38 0.4 2,701 27 0.3 1.40 0.86 2.30 0.28
(Non-Hispanic) 
Black
1,379 11 0.3 1,379 11 0.3 1.03 0.45 2.38
Hispanic 503 2 0.1 481 0 0.0 – – –
Syncope (Non-Hispanic) 
White
2,698 39 0.5 2,701 31 0.4 1.24 0.77 1.99 0.94
(Non-Hispanic) 
Black
1,379 9 0.2 1,379 7 0.2 1.32 0.49 3.56
Hispanic 503 5 0.3 481 3 0.2 1.59 0.38 6.66
Bradycardia (Non-Hispanic) 
White
2,698 32 0.4 2,701 29 0.3 1.10 0.66 1.81 0.30
(Non-Hispanic) 
Black
1,379 4 0.1 1,379 8 0.2 0.51 0.15 1.70





2,698 48 0.6 2,701 37 0.4 1.29 0.84 1.98 0.11
(Non-Hispanic) 
Black
1,379 16 0.4 1,379 13 0.3 1.27 0.61 2.64
Hispanic 503 4 0.3 481 0 0.0 – – –
Injurious fallc (Non-Hispanic) 
White
2,698 93 1.1 2,701 115 1.4 0.80 0.61 1.05 0.11
(Non-Hispanic) 
Black
1,379 26 0.6 1,379 21 0.4 1.28 0.72 2.27





2,698 66 0.8 2,701 49 0.6 1.34 0.93 1.94 0.46
(Non-Hispanic) 
Black
1,379 43 1.0 1,379 23 0.5 1.95 1.17 3.23
Hispanic 503 6 0.4 481 5 0.3 1.15 0.35 3.78
Abbreviation: CI, confidence interval, SAE, serious adverse event.
aSAEs were defined as an adverse experience judged by an investigator to be life threatening and/or resulting in death, permanent disability, 
hospitalization, or prolongation of hospitalization, whether or not the event was thought to be related to the study intervention.
bElectrolyte abnormality were adverse laboratory measures detected on routine or unscheduled tests; routine laboratory tests were per-
formed at 1 month, then quarterly during the first year, then every 6 months.
cAn injurious fall was defined as a fall that resulted in evaluation in an emergency department or that resulted in hospitalization.
dAcute kidney injury or acute renal failure were based on a primary or secondary diagnosis listed in the hospital discharge summary and was 
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SPRINT was not significantly higher than that of NHWs in 
SPRINT, which is not a representation of that found in the 
overall community. However, SPRINT assessment of race 
and ethnicity was through self-designation which also has 
its limitations.34 NHBs and Hispanics are admixed popu-
lations, and the US concept of race being only White or 
Black is seen as confusing35 and may have caused signifi-
cant misclassification when trying to dichotomize White 
Hispanics and Black Hispanics.36 Finally, the small sample 
size of Hispanics limited meaningful comparisons making 
the analysis of Hispanics underpowered and potentially 
unstable.
The clinical implications of the SPRINT results are sub-
stantial. Considering the high prevalence of hypertension 
and uncontrolled hypertension among NHBs and Hispanics, 
intensive SBP lowering is bound to have a greater pub-
lic health impact among these populations.4 Importantly, 
achieving lower SBP targets in NHB will require more anti-
hypertensive therapy to achieve this goal. Our results indi-
cate that most individuals above age 50  years with higher 
than average cardiovascular risk profile and SBP ≥130 mm 
Hg, including many above age 75  years old regardless of 
racial/ethnic origin benefit from treating to a SBP target of 
<120 mm Hg.
Overall, SPRINT findings showed benefit of a <120 mm 
Hg target (compared to one <140  mm Hg) in the NHB, 
Hispanic, and NHW populations and provide no evidence 
for heterogeneity of effect by race or ethnicity.
SUPPLEMENTARY MATERIAL
Supplementary data are available at American Journal of 
Hypertension online.
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